{"id":"NCT01428635","sponsor":"M.D. Anderson Cancer Center","briefTitle":"Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy","officialTitle":"Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-01-13","primaryCompletion":"2022-01-03","completion":"2022-01-03","firstPosted":"2011-09-05","resultsPosted":"2023-02-01","lastUpdate":"2023-09-26"},"enrollment":21,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Primary Myelofibrosis","Thrombocytopenia"],"interventions":[{"type":"DRUG","name":"Eltrombopag Olamine","otherNames":["Promacta","SB-497115-GR"]}],"arms":[{"label":"Supportive care (eltrombopag olamine)","type":"EXPERIMENTAL"}],"summary":"This phase II/III trial studies how well eltrombopag olamine works in treating thrombocytopenia in patients with chronic myeloid leukemia or myelofibrosis receiving tyrosine kinase inhibitor therapy. Eltrombopag olamine may cause the body to make platelets after receiving treatment for chronic myeloid leukemia or myelofibrosis.","primaryOutcome":{"measure":"Number of Participants With a Platelet Response","timeFrame":"Up to 9 years","effectByArm":[{"arm":"Supportive Care (Eltrombopag Olamine) CML Participants","deltaMin":12,"sd":null},{"arm":"Supportive Care (Eltrombopag Olamine) Myelofibrosis Participants","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.mdanderson.org"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":15},"commonTop":["Alanine aminotransferase increased","Aspartate aminotransferase increased","Fatigue","Diarrhea","Insomnia"]}}